Self Protection from Anti-Viral Responses – Ro52 Promotes Degradation of the Transcription Factor IRF7 Downstream of the Viral Toll-Like Receptors by Higgs, Rowan et al.
Self Protection from Anti-Viral Responses – Ro52
Promotes Degradation of the Transcription Factor IRF7
Downstream of the Viral Toll-Like Receptors
Rowan Higgs
1, Elisa Lazzari
1, Claire Wynne
1, Joan Nı ´ Gabhann
1, Alexander Espinosa
2, Marie
Wahren-Herlenius
2, Caroline A. Jefferies
1*
1Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland, 2Department of Medicine, Karolinska Institutet,
Stockholm, Sweden
Abstract
Ro52 is a member of the TRIM family of single-protein E3 ligases and is also a target for autoantibody production in systemic
lupus erythematosus and Sjo ¨gren’s syndrome. We previously demonstrated a novel function of Ro52 in the ubiquitination
and proteasomal degradation of IRF3 following TLR3/4 stimulation. We now present evidence that Ro52 has a similar role in
regulating the stability and activity of IRF7. Endogenous immunoprecipitation of Ro52-bound proteins revealed that IRF7
associates with Ro52, an effect which increases following TLR7 and TLR9 stimulation, suggesting that Ro52 interacts with
IRF7 post-pathogen recognition. Furthermore, we show that Ro52 ubiquitinates IRF7 in a dose-dependent manner, resulting
in a decrease in total IRF7 expression and a subsequent decrease in IFN-a production. IRF7 stability was increased in bone
marrow-derived macrophages from Ro52-deficient mice stimulated with imiquimod or CpG-B, consistent with a role for
Ro52 in the negative regulation of IRF7 signalling. Taken together, these results suggest that Ro52-mediated ubiquitination
promotes the degradation of IRF7 following TLR7 and TLR9 stimulation. As Ro52 is known to be IFN-inducible, this system
constitutes a negative-feedback loop that acts to protect the host from the prolonged activation of the immune response.
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Introduction
A critical step in the innate immune response to viral infection is
the production of type I IFN (IFN-a and -b) [1]. In particular, the
regulatory networks that regulate that activity of the IFN
regulatory factor (IRF) family members IRF3 and IRF7 have
been an area of intense study of late [2,3,4,5,6]. Indeed, a number
of endogenous and viral proteins have recently been described
which positively or negatively regulate the activity of IRF
family members, thus manipulating the type I IFN response
[7,8,9,10,11,12,13].
The cellular mechanisms involved in IRF7-mediated type I IFN
gene induction have been studied intensely in recent years. The
ubiquitin E3 ligase TNF receptor-associated factor 6 (TRAF6) is
known to ubiquitinate IRF7 in a K63-dependent manner
following TLR stimulation, resulting in IRF7 activation and the
initiation of IFN-a transcription [14]. This effect has been shown
to depend on the formation of a complex between IRF7, TRAF6
and MyD88 and is critical for type I IFN production downstream
of TLR7, TLR8 and TLR9 stimulation [14,15]. Furthermore, the
E3 ligase activity of TRAF6 is also known to be required for latent
membrane protein 1 (LMP1)-stimulated IRF7 ubiquitination and
may be a prerequisite for IRF7 phosphorylation by IKKa, IKKe,
TANK-binding kinase 1, or IL-1 receptor-associated kinase 1
[16,17,18]. Following IRF7-mediated induction of type I IFNs, it
is known that IRF7 is rapidly degraded in order to protect the host
from excessive production of IFNs [19]. However, the endogenous
E3 ligase responsible for initiating the degradation of IRF7 as part
of the normal immune response has not yet been identified.
Ro52 (also denoted TRIM21 and SSA1) is a member of the
tripartite motif (TRIM) family of single-protein E3 ligases and is
known to be a target for autoantibody production in systemic
lupus erythematosus and Sjo ¨gren’s syndrome [20,21,22,23,24,25].
Ro52 expression is known to IFN-inducible and through several
recent studies, is emerging as a critical regulator of IRF stability.
Work performed in our lab described a novel function of Ro52 in
the negative regulation of IFN-b production following TLR3/4
stimulation. Ro52 achieves this by promoting the ubiquitination
and proteasomal degradation of IRF3 [13]. Furthermore, through
the generation of Ro52-deficient mice, Ro52 has recently been
implicated in a type I IFN negative feedback loop, responsible for
limiting the production of type I IFNs and for preventing the onset
of an IL-23p19-mediated lupus-like disease [26].
To date the endogenous cellular mechanism to turn off IRF7
signalling has not been described. In this study we provide the first
evidence that Ro52 and IRF7 associate endogenously, leading to
the ubiquitination and subsequent degradation of IRF7. These
results are consistent with the reported effects of Ro52 deficiency
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11776in mice, thus adding further evidence that Ro52 functions as part
of a negative feedback loop to protect the host from the deleterious
effects of prolonged type I IFN production.
Results
Ro52 associates endogenously with IRF7
We have previously shown that recombinant Ro52 interacts
with both overexpressed IRF3 and IRF7 in a pulldown experiment
[13]. In order to confirm the association of Ro52 with endogenous
IRF7 and to examine the status of this relationship following TLR
stimulation, HeLa cells were stimulated with either polyI:C,
lipopolysaccharide (LPS), imiquimod or CpG-B for 4 and
18 hours. Cell lysates were immunoprecipitated with an anti-
Ro52 antibody and IRF7 association was detected by immuno-
blotting with an anti-IRF7 antibody (Figure 1). A weak
endogenous association was observed in unstimulated cells,
confirming our previous result [13]. Interestingly, this interaction
increased following LPS, imiquimod and CpG-B stimulation and
to a lesser extent following 2 hours polyI:C stimulation. The
interaction between Ro52 and IRF7 was maintained at 18 hrs
LPS stimulation, whereas following imiquimod stimulation, the
association between Ro52 and IRF7 was observed to increase at
18 hours. By contrast, a decrease in Ro52-IRF7 interaction was
observed at 18 hrs CpG-B stimulation. Importantly, the changes
observed in Ro52-IRF7 interaction were not due to fluctuations in
either Ro52 or IRF7 levels in the cells as demonstrated in Figure 1.
This results suggests that Ro52 targets IRF7 following TLR
stimulation and that the longevity of this interaction is TLR-
specific.
Ro52 ubiquitinates IRF7 in a dose-dependent manner
As Ro52 is known to ubiquitinate both IRF3 and IRF8, we next
examined the potential of Ro52 to ubiquitinate IRF7 in a co-
transfection experiment. Human embryonic kidney (HEK) 293T
cells were transfected with plasmids expressing Flag-IRF7, Xpress-
Ro52 and hemagglutinin (HA)-ubiquitin and cell lysates were
immunoblotted with various antibodies. Our results clearly show
that IRF7 is polyubiquitinated only when it is co-expressed with
Ro52 and HA-ubiquitin (Figure 2A). Increasing amounts of Ro52
resulted in a dose-dependent increase in IRF7 ubiquitination
(Figure 2B), indicating that this effect is directly regulated by Ro52.
These results demonstrate the ability of Ro52 to add ubiquitin
moieties to IRF7, and combined, these results strongly suggest that
Ro52 targets IRF7 for ubiquitination following TLR stimulation.
To confirm that the observed higher molecular weight bands were
indeedubiquitinatedformsofIRF7,HEK293Tcellsweretransfected
with plasmids expressing Flag-IRF7, Xpress-Ro52 and HA-ubiquitin
and cell lysates were immunoprecipitated with both anti-Flag and
anti-HA antibodies. Following immunoprecipitation of Flag-IRF7-
bound proteins, an immunoblot was performed for Flag to confirm
the expression of IRF7 and the ability of the Flag antibody to
successfullybindtotheIgGsepharosebeads(Fig.2C,secondpanel,lanes
2–4). The same membrane was then immunoblotted for HA-
ubiquitin and revealed the presence of polyubiquitinated IRF7 only
in the lane expressing both ubiquitin and Ro52 (Fig. 2C, upper panel,
lane 4). This effect was also observed by immunoprecipitating HA-
ubiquitin bound proteins followed by a Flag-IRF7 immunoblot
(Fig. 2C, lower panel, lane 4). Together our results clearly show that
IRF7 and Ro52 interact following TLR stimulation and that this
i n t e r a c t i o ns e r v e sa sam e a n st op o l y u b i q u i t i n a t eI R F 7 .
During the ubiquitinaiton process, the specific lysine on the
ubiquitin molecule used by the E3 ligase to attach it to the target
protein often determines the fate of the protein. To determine
whether Ro52 ubiquitinates IRF7 in a K48- or K63-dependent
manner, specific ubiquitin mutants were used, in which all lysines
in the ubiquitin sequence were mutated to arginine, with the
exception of either K48 (ubiquitin R48K mutant) or K63
(ubiquitin R63K mutant). Co-expression of Flag-IRF7, Xpress-
Ro52 and either HA-ubiquitin R48K or HA-ubiquitin R63K
resulted in a considerable decrease in IRF7 polyubiquitination in
comparison to full length HA-ubiquitin, suggesting that both the
K48 and K63 residues are involved in the Ro52-mediated
polyubiquitination of IRF7 (Figure 2D). Interestingly, in the
absence of Ro52, ubiquitination of IRF7 was not observed when
expressed with R48K, suggesting that Ro52 may be important in
mediating K48-linked polyubiquitination of IRF7. As expected,
the presence of overexpressed Ro52 markedly increased IRF7
polyubiquitination, although IRF7 was still ubiquitinated by
endogenous E3 ligases (which include Ro52).
Ro52 inhibits IRF7-driven IFNa4-reporter gene activation
PreviousworkbyEspinosaetalhas clearly shownthat TLR7-and
TLR9-mediated gene induction is significantly altered in Ro52-
deficientmice.SpecificallybothIFN-a andIFN-b wereenhanced in
splenocytes derived from Ro52-deficient mice compared with wild-
type controls following infection with herpes simplex virus (HSV)-2,
stronglysuggestingthatRo52 isanegativeregulatorofIRF7activity
[26]. To test this hypothesis and to determine the effect of Ro52 on
IRF-mediated IFN production, HEK293T cells were transfected
with plasmids expressing IRF7, the IFN-a promoter and increasing
amounts of Ro52. Whilst transfection of cells with an empty control
vector did not drive IFN-a promoter activity, transfection with a
plasmid expressing IRF7 resulted in efficient stimulation of the IFN-
a promoter (Fig. 3A). The addition of increasing concentrations of a
plasmid expressing Ro52 significantly inhibited IRF7-driven IFN-a
promoter activity in a dose-dependent manner. In contrast,
increasing amounts of a plasmid expressing a mutant Ro52 lacking
the really interesting new gene (RING)-finger domain, required for
the E3 ligase activity of Ro52, failed to significantly inhibit IRF7-
driven IFN-a promoter activity (Fig. 3B). Taken together, these
results confirm that the observed inhibition of the IFN-a4 promoter
is mediated by full-length active Ro52, indicative of a role for Ro52
as a negative regulator of IRF7-driven type I IFN production.
Ro52 negatively regulates IRF7 expression by initiating
IRF7 degradation
To determine the mechanism by which Ro52 negatively
regulates the IFN-a4 promoter we examined the fate of IRF7
Figure 1. Ro52 interacts with IRF7. HeLa cells were stimulated with
the indicated ligands for 4 and 18 hrs. Cell lysates were immunopre-
cipitated with an anti-Ro52 antibody and immunoblotted with an anti-
IRF7 antibody, an anti-Ro52 antibody and an anti-a-actinin antibody.
doi:10.1371/journal.pone.0011776.g001
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with plasmids expressing Flag-IRF7, HA-ubiquitin and increasing
Xpress-Ro52. In this experiment, in contrast to that shown in
Figure 2, the amount of Flag-IRF7 expressing plasmid transfected
into the cells was significantly reduced in order that the effect
of Ro52 on IRF7 fate might be observed. Cell lysates were
Figure 2. Ro52 ubiquitinates IRF7. (A) HEK293T cells were transfected with 1 mg of the indicated constructs for 18 hrs. Presence of Flag-IRF7, HA-
ubiquitin, Xpress-Ro52 and b-actin was detected by immunoblotting. (B) HEK293T cells were transfected with 500 ng of Flag-IRF7, 1 mg of HA-
ubiquitin and increasing amounts of Xpress-Ro52 (500 ng, 1 mg and 2 mg) for 18 hrs. Presence of Flag-IRF7, HA-ubiquitin, Xpress-Ro52 and b-actin
was detected by immunoblotting. (C) HEK293T cells were transfected with 500 ng of Flag-IRF7, 1 mg of HA-ubiquitin and 500 ng of Xpress-Ro52 for
18 hrs. Flag-IRF7-bound proteins and HA-ubiquitinated proteins were immunoprecipitated from HEK293T cell lysates with anti-Flag and anti-HA
antibodies. Presence of HA-ubiquitinated Flag-IRF7 was detected by immunoblotting. (D) HEK293T cells were transfected with 500 ng of Flag-IRF7,
1 mg of HA-ubiquitin plasmids (both WT and mutants) and 500 ng of Xpress-Ro52 for 18 hrs. Flag-IRF7-bound proteins and HA-ubiquitinated proteins
were immunoprecipitated from HEK293T cell lysates with anti-HA antibodies. Presence of HA-ubiquitinated Flag-IRF7, HA-ubiquitin, and Xpress-Ro52
was detected by immunoblotting.
doi:10.1371/journal.pone.0011776.g002
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time, Ro52-induced IRF7 degradation was observed, an effect
which was substantially increased at the highest concentration
of Ro52 (Figure 4A). This result indicates that Ro52 targets IRF7
for polyubiquitination in order to induce degradation of the
transcription factor post-TLR stimulation. Furthermore, this
Ro52-mediated degradation of IRF7 was inhibited in the presence
of MG132, a proteasome inhibitor, indicating that IRF7 is
targeted to the proteasome for degradation (Figure 4B).
In order to investigate the effects of Ro52 deficiency on IRF7
levels in primary immune cells, we used bone-marrow derived
macrophages (BMDMs) from Ro52-deficient mice, which display
enhanced type I IFN production following TLR stimulation [26].
As IRF7 is a key transcription factor which regulates the
expression of type I IFNs, we analyzed IRF7 expression following
TLR7 and TLR9 stimulation in BMDMs from wildtype and
Ro52-deficient mice. As shown in Figure 4C and 4D, in wild type
mice, IRF7 was induced following 3 hours stimulation with either
imiquimod (Figure 4C) or CpG-B (Figure 4D). However, in Ro52-
deficient mice a substantial increase in IRF7 induction was
observed, which peaked at 6 hrs following imiquimod stimulation
and at 3 hrs following CpG-B stimulation. This result is consistent
with the Ro52-mediated ubiquitination and degradation observed
in the HEK293T cells, and suggests that in the absence of Ro52,
IRF7 levels accumulate following TLR-7 and TLR-9 stimulation,
thus contributing to the enhanced IFN responses observed in the
knockout mice [26]. Taken together, these findings indicate that
Ro52 functions to limit IRF7 induction following TLR7 and
TLR9 activation, similar to the previously described role for Ro52
in the negative regulation of IRF3 following TLR3 and TLR4
activation and consistent with the reported effects of Ro52
deficiency in mice.
Discussion
Recentworkhasdemonstrated thatlossofRo52canleadtotissue
inflammation and systemic autoimmunity through activation of the
IL-23/TH17 axis and has clearly established Ro52 as an important
negative regulator of proinflammatory cytokine and type I IFN
production (26). Work prior to this had demonstrated that Ro52
could interact with IRF3 and IRF8 and regulate the stability levels
of these transcription factors through the ubiquitin-proteasome
system[13,27].Weobservedinanearlierstudythat Ro52associates
with overexpressed IRF7 and speculated that Ro52 might regulate
this transcription factor and other IRF family members [13]. We
now present evidence identifying Ro52 as an endogenous E3 ligase
that negatively regulates IRF7 expression. Endogenous immuno-
precipitation of Ro52-bound proteins revealed that IRF7 associates
with Ro52, an effect which increases following TLR7 and TLR9
stimulation. This suggests that Ro52 interacts with IRF7 post-
pathogen recognition and may function as a regulator of IRF7
stability, similarly to its role in regulating IRF3 [13].
Regulation of IRF7 stability is a potent mechanism of
controlling type I IFN production in response to viral infection
and has previously been shown to be highly cell specific [19].
Several viral proteins have been identified which encode E3 ligases
and promote IRF7 degradation via the ubiquitin-proteasome
system. The Kaposi’s sarcoma-associated herpesvirus (KSHV)-
encoded immediate-early replication and transcription activator
(RTA) protein targets IRF7 for proteasomal degradation [12], as
does the rotaviral non-structural protein 1 [9]. The function of
these viral proteins is presumably to inhibit the anti-viral response
by degrading IRF7; however the endogenous E3 ligase responsible
for degrading IRF7 as a protective measure against the harmful
effects of type I IFN overproduction has remained elusive to date.
Our data indicates that Ro52 ubiquitinates IRF7, adding both
monoubiquitin and polyubiquitin chains to the transcription
factor. A previous study identified that degradation of IRF7 was
ubiquitin-dependent, through use of a dominant-negative form of
the Skp, Cullin, F-box (SCF) ubiquitin ligase complex protein
Cul1 [19]. Accordingly, we observed a dose-dependent decrease in
IRF7 levels when expressed with constant ubiquitin and increasing
amounts of Ro52 indicating that, like Cul1, Ro52 promotes
degradation of IRF7.
Figure 3. Ro52 inhibits IFN-a4 reporter gene activation. HEK293T cells were transfected with a reporter construct containing the IFN-a4
promoter. Cells were co-transfected with 50 ng IRF7 or empty vector (EV) control and increasing amounts of (a) Ro52-expressing construct or (b) a
plasmid expressing a Ro52 mutant lacking the RING-finger domain. Cells were assayed for reporter gene activity 18 hrs post-transfection. *, p,0.01 as
determined by Student’s t test. NS, not significant.
doi:10.1371/journal.pone.0011776.g003
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including severe dermatitis, systemic lupus with hypergamma-
globulinemia and autoantibodies to DNA, indicating that a loss of
Ro52 can cause a lupus-like disease [26]. We observed a
substantial increase in IRF7 induction in bone marrow-derived
macrophages from Ro52-deficient mice stimulated with both
imiquimod and CpG-B, when compared to wildtype mice. This
result is consistent with a role for Ro52 in the negative regulation
of IRF7 signalling. Thus, it seems likely that whilst TRAF6-
mediated monoubiquitination activates IRF7, Ro52-mediated
polyubiquitination promotes the degradation of IRF7 following
TLR7 and TLR9 stimulation.
This novel role for Ro52, in negatively regulating IRF7 stability,
may provide a mechanism to protect the host from the
overproduction of type I IFNs, a contributing factor to the
pathogenesis of systemic lupus erythematosus [28]. This hypoth-
esis is supported by the ability of Ro52 to dose-dependently inhibit
luciferase activation by the IFN-a4 promoter when stimulated
with IRF7. In addition, bone marrow-derived macrophages from
Ro52-deficient mice have previously been shown to produce
increased levels of type I IFNs and proinflammatory cytokines
following stimulation with TLR9 ligands [26], an effect which can
now be explained by the negative regulation of IRF7 signalling by
Ro52. Several studies have shown that Ro52 plays a dual role in
regulating IRF family member stability [13,26,27,29,30]. These
observations, along with the results presented here, suggest that
Ro52 has a complex role in regulating innate immune responses,
and may be involved in both the activation and degradation of
IRF family members. In addition, regulation of IRF7 is not solely
controlled by the classical ubiquitin-proteasome system, as recent
studies have shown a role for SUMOylation [31] and the
translational repressors 4E-BP1 and 4E-BP2 [32] in inhibiting
IRF7 signalling. It is likely that Ro52 lies downstream of both
TLRs and the RLRs such as RIG-I, similar to its role in regulating
IRF3 stability [13]. The precise mechanism by which the activity
of Ro52 is regulated downstream of both TLRs and RLRs is
currently being investigated in our lab.
In summary, we provide evidence that Ro52 functions to
degrade IRF7 following TLR7 and TLR9 stimulation. These
receptors are nucleic acid-sensing TLRs known to be involved in
the pathogenesis of autoimmune diseases such as systemic lupus
erythematosus. In addition, it has been postulated by us and others
that Ro52, an IFN-inducible ubiquitin ligase, is central to a
negative feedback loop which protects the host from prolonged
exposure to type I IFNs [33]. This is consistent with both the
established role of Ro52 in negatively regulating IRF3 expression
post TLR3 and TLR4 stimulation and the novel role of Ro52,
reported here, in ubiquitinating and degrading IRF7. Taken
together with reports of Ro52 regulating other IRF family
members, both positively and negatively, Ro52 is emerging as a
multifunctional protein with a critical role in regulating innate
immune responses. Further studies may identify approaches to
Figure 4. Ro52 mediates its effects by destabilising IRF7. (A) HEK293T cells were transfected with 500 ng of Flag-IRF7, 1 mg of HA-ubiquitin
and increasing amounts of Xpress-Ro52 (500 ng, 1 mg and 2 mg) for 18 hrs. Presence of Flag-IRF7, HA-ubiquitin, Xpress-Ro52 and b-actin was
detected by immunoblotting. (B) HEK293T cells were transfected with 500 ng of Flag-IRF7, 1 mg of HA-ubiquitin and 500 ng of Xpress-Ro52 for
18 hrs. Transfected cells were treated with either MG132 or DMSO for 2 hours prior to cell lysis. Presence of Flag-IRF7, Xpress-Ro52 and a-actinin was
detected by immunoblotting. (C and D) Bone marrow-derived macrophages from wildtype and Ro52-deficient mice were stimulated with either (C)
10 mg/ml imiquimod or (D) 3 mM CpG-B at the indicated timepoints. Expression of IRF7 and b-actin were detected by immunoblotting. IRF7
expression was quantitated by densitometry following normalisation to b-actin expression as indicated in accompanying graphs.
doi:10.1371/journal.pone.0011776.g004
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strategies to help prevent autoimmune disease.
Materials and Methods
Cell culture
HEK293T cells and HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% foetal
calf serum (FCS) and 10 mg/ml gentamicin. The generation of
Ro52 knockout mice has been described previously [26]. Bone
marrow-derived macrophages were harvested from femurs
obtained from wildtype and Ro52-deficient mice and cultured in
DMEM supplemented with 10% FCS, 10 mg/ml gentamicin and
10–15% L929 supernatant for 6–8 days prior to being stimulated
with imiquimod or CpG-B/IFN-c.
Plasmids and reagents
Flag-tagged IRF7, pEF-Bos-TRIF-Flag and the IFNa4 promoter-
luciferase constructs were from Dr. Kate Fitzgerald (University of
Massachusetts Medical School, Worcester, MA). Wildtype and
DExon1 Xpress-tagged Ro52 constructs were provided by Dr. David
Rhodes (Cambridge Institute for Medical Research, Cambridge,
UK) and HA-ubiquitin, HA-ubiquitin R48K, and HA-ubiquitin
R63K plasmids were from Dr. Andrew Bowie (School of
Biochemistry with Immunology, Trinity College Dublin, Ireland).
Primary antibodies used were anti-HA, anti-IRF7 (both Santa Cruz
Biotechnologies), anti-Flag (Sigma), anti-Xpress
TM (Invitrogen), a-
actinin (Santa Cruz Biotechnologies) and anti-b-actin (Abcam).
Polyclonal antibodies against Ro52 that were used in immunopre-
cipitation experiments were made by Sigma-Genosys and anti-Ro52
antibodies used in Western blots were purchased from BioReagents,
Cambridge, UK.
Luciferase reporter gene assays
HEK293T cells were transfected with an IFNa4 promoter-
luciferase construct, an IRF7 construct (50 ng) and increasing
amounts of a wildtype or DExon1 Ro52 construct (10 ng, 50 ng
and 100 ng). All transfections were performed using Metafecte-
ne
TM (Biontex) according to the manufacturer’s recommenda-
tions. Following transfection, luciferase activity was standardized
to Renilla luciferase plasmid activity to normalize for transfection
efficiency. Each luciferase is representative of three independent
experiments.
Immunoprecipitation
Cells were lysed on ice in 16 radioimmune precipitation lysis
buffer (16PBS, 1% Nonidet P-40, 0.5% Na-deoxycholate, 0.1%
SDS, 1 mM KF, 1 mM Na3VO4,1 0mg/ml leupeptin and 1 mM
phenylmethylsulfonyl fluoride) followed by immunoprecipitation
with either anti-HA agarose, or anti-Flag or anti-Ro52 bound to
protein-G sepharose beads, as indicated in the figure legends.
Immunoprecipitates were analysed by Western blot. Each blot is
representative of up to three independent experiments.
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